ERBB2 and gastric adenocarcinoma: High CNV had been revealed as an independent risk factor predicted unfavorable prognosis in HER2-positive gastric adenocarcinoma patients (38), and HER2-positive metastatic breast cancer patients with high HER2 CNV in plasma had worse prognosis after trastuzumab-based therapy (39).